Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Chloride-transporting synthetic molecules show promise

Researchers have developed new synthetic molecules that can transport chloride salts across cell membranes, which showed promise for restoring normal mucus production in a cell model of cystic fibrosis (CF), a new study shows. “One day, [these molecules] could be leveraged into a drug that treats cystic fibrosis,” Bing…

Low T common, but likely underdiagnosed, in men with CF

Men with cystic fibrosis (CF) commonly have low testosterone levels, though this is likely underrecognized due to a lack of testing, a new study highlights. The findings underscore the importance of checking testosterone levels in men with CF so that interventions can be discussed if warranted, researchers said in…

Achromobacter bacteria seen as new target to fight CF infections

A type of bacteria called Achromobacter, which can cause problematic lung infections in people with cystic fibrosis (CF), uses a molecular weapon — one known as a type 3 secretion system — to induce a powerful inflammatory response during infections, a new study found. “These bacteria resist the action…

Support groups, clear advice needed by parents living with CF

As more adults with cystic fibrosis (CF) choose to become parents, they face unique challenges in balancing the responsibilities of caring for their children and managing their disease, a study highlights. Researchers outlined several areas where care teams could be of help, such as working with prospective parents to…

3D MRI of lungs seen to help measure Trikafta response in study

A three-dimensional MRI scan of the lungs can be used to monitor responses by cystic fibrosis (CF) patients to the approved CF medication Trikafta (elexacaftor/tezacaftor/ivacaftor), a new study reports. Indeed, the new 3D technology was found to work better than traditional two-dimensional MRI scans in assessing the effects of Trikafta…